ABPath Combined AP/CP Primary Certification common mistakes
ABPath Combined AP/CP Primary Certification · Understand the traps and how to avoid them.
On an antibody identification panel, selecting a single specificity from the first panel and stopping without completing rule-out with homozygous cells or excluding a second antibody.
Pattern recognition under time pressure; enzyme-treated panels can enhance some antibodies and weaken others, and dosage effects are easy to overlook.
What to do instead
Use a written rule-out worksheet: require at least three antigen-positive, crossmatch-incompatible cells or homozygous rule-out cells per specificity; repeat with an untreated panel, selected cells, and adsorption when panreactivity or multiple specificities are present.
In a suspected delayed hemolytic transfusion reaction, ordering only a repeat ABO/Rh and DAT and concluding 'negative' when the DAT is negative or only weakly positive.
The DAT can be negative in delayed reactions, and the workup often stops at the front type; eluate and adsorption are skipped.
What to do instead
Obtain pre- and post-transfusion samples, perform DAT with polyspecific and monospecific antisera, eluate, and alloadsorption; correlate with bilirubin/LDH/haptoglobin and review transfusion history for 3–14 days.
Accepting a markedly discordant chemistry result (e.g., normal creatinine with very high urea, or an impossible electrolyte combination) without checking for hemolysis, lipemia, icterus, or biotin/heterophile interference.
Automated analyzers flag only what they are programmed to flag, and delta checks are often ignored when the result 'fits' a clinical story.
What to do instead
Apply a reflex interference screen: inspect the specimen index, dilute and re-run for linearity, use an alternate method (e.g., creatinine enzymatic vs Jaffe), and test for heterophile/biotin interference when the clinical picture is inconsistent.
Interpreting serum protein electrophoresis and immunofixation as a single monoclonal band without distinguishing oligoclonal bands, small M-proteins, or light-chain-only disease.
IFE bands can be over-read; free light chain ratio and immunoparesis are not integrated.
What to do instead
Integrate SPEP, IFE, serum/urine free light chains, and quantitative immunoglobulins; use an antisera panel and dilution to resolve small bands; recommend bone marrow/biopsy only when the whole pattern supports clonality.
Making a diagnosis of a mature B-cell neoplasm from morphology and a single flow marker, without a complete flow panel or Matutes score.
Morphology overlaps; flow panels are often truncated under time pressure; small clones can be missed.
What to do instead
Require a complete B-cell tube (CD5, CD10, CD19, CD20, CD22, CD23, CD43, CD79b, FMC7, surface Ig) and integrate with CBC, smear, and cytogenetics (t(11;14), del(17p)).
Overcalling dysplasia in a marrow with megaloblastic or reactive changes, or missing ring sideroblasts because the iron stain was not reviewed.
Megaloblastic anemia and MDS share nuclear-cytoplasmic asynchrony; iron stain is often ordered but not correlated.
What to do instead
Check B12/folate and TSH, review iron stain for ≥5% ring sideroblasts, and use cytogenetics/flow; avoid a definitive MDS diagnosis without persistent cytopenias and supporting clonal markers.
Treating a single coagulase-negative Staphylococcus blood culture or a mixed sputum culture as a true pathogen and escalating antibiotics.
Culture reports lack clinical context; contamination and colonization are common; time pressure favors action.
What to do instead
Apply contamination criteria: require two or more positive bottles with the same organism and clinical signs; review Gram stain and colony count for sputum; correlate with imaging and host status before treating.
Applying the wrong breakpoint system or missing intrinsic resistance (e.g., reporting ampicillin susceptible for Klebsiella or using an outdated CLSI table).
Breakpoints change yearly; labs may mix CLSI and EUCAST; automated panels may not flag intrinsic resistance.
What to do instead
Use the current CLSI M100 or EUCAST table consistently; verify intrinsic resistance rules for the organism; confirm ESBL/AmpC/carbapenemase phenotypes with a second method.
Responding to a single QC rule violation by repeating the control until it passes, without investigating the run.
1-3s and 2-2s rules are misunderstood; staff treat QC as a checkbox; repeat testing hides shifts.
What to do instead
Apply Westgard multirules with a written algorithm; for 1-3s, repeat once, then investigate; for 2-2s, 4-1s, and 10x, reject and troubleshoot calibration/reagent/specimen.
After a proficiency testing failure, filing a corrective action that only says 're-educate staff' without root cause, or missing the required PT failure investigation and reporting timeline.
PT failures are handled by the bench supervisor; regulatory timelines and the need to distinguish test-system from clerical error are not well known.
What to do instead
Conduct a documented root-cause analysis distinguishing clerical, methodological, and system errors; implement a specific corrective action with monitoring; know the CAP/CLIA definition of unsuccessful PT performance and report within the required timeline.